Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-NOTA-CD70 antibody fragment
- Development stage
- Phase 1
- Lead developer
- Union Hospital of Huazhong University of Science and Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[68Ga]Ga-NOTA-CD70 antibody fragment is a radiopharmaceutical diagnostic agent developed by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. It consists of an antibody fragment specific for CD70, conjugated with the NOTA chelator and labeled with the positron-emitting radioisotope Gallium-68 (68Ga). CD70 is a transmembrane protein and a member of the tumor necrosis factor (TNF) superfamily that is highly expressed in renal cell carcinoma (RCC) but has restricted expression in normal tissues. This imaging agent is designed for use with PET/CT or PET/MR to detect, stage, and monitor RCC by targeting the CD70 protein on tumor cells, providing a molecular imaging tool to assess tumor burden and expression levels.
- Other names
- 68Ga-NOTA-CD70Gallium-68 NOTA-CD70 antibody fragmentGallium68 NOTA-CD70 antibody fragmentGallium 68 NOTA-CD70 antibody fragment
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on [68Ga]Ga-NOTA-CD70 antibody fragment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-NOTA-CD70 antibody fragment.